Syngene is powered by its twin growth engines – research or CRO services, which includes the dedicated centers; and CDMO services, which encompasses drug development and manufacturing.
Syngene’s Research Services: Our Drug Discovery division conducts early stage research, from identifying biological targets relevant to disease in patient populations – to delivering drug candidates for further development.  SynVentâ„¢, is an integrated drug discovery platform that offers clients end-to-end discovery programs, delivering exponential value through co-localization of world-class scientific teams across the discovery continuum. The SynVent team works with diverse biological entities including monoclonal antibodies, bispecifics, recombinant proteins and mRNA.
Syngene’s Biologics Discovery services is a one-stop shop for all the initial stages of developing new biologic drugs, from identifying the molecules involved in the diseases to creating potential treatments. We achieve this through a range of techniques, including pinpointing specific targets, engineering cells for drug production, developing custom antibodies, utilizing advanced gene sequencing for analysis, and studying proteins to understand their role in disease.
Syngene’s unique business model allows us to offer R&D services that are flexible and designed to suit our client’s needs. The Dedicated R&D Centers model includes expanded and integrated services, where we set up dedicated, customized and ring-fenced facilities. This involves long-term strategic collaborations, usually for five-year periods or longer. Currently, Syngene operates dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb.
Syngene’s Development and Manufacturing Services: The Development Services division provides a range of services, from pre-clinical to clinical trials, including drug substance, drug product development and other associated services that demonstrate the safety, tolerability and efficacy of drugs. Our development capabilities include advancing highly potent active pharmaceutical ingredients (HPAPI) and oligonucleotides with therapeutic and diagnostic applications, from laboratory to manufacturing scale.  Syngene integrates analytical services such as method development, validation, transfer and reference standard qualification throughout the development process.
Manufacturing Services: Syngene offers manufacturing solutions for small and large molecules. We have the capability to scale up manufacturing from laboratory volumes to commercial levels seamlessly, in tandem with Good manufacturing practices (cGMP). All our scale-up activities are performed by an experienced team who are supported by other divisions such as quality control, quality assurance, environment health safety and sustainability, engineering and maintenance and supply chain management.
As a fully integrated custom biomanufacturer, our solutions include mammalian and microbial capabilities for clinical and commercial supplies. Our expertise spans a broad spectrum including various forms of antibodies, simple and complex proteins, even genetic material like mRNA. Syngene’s biologics manufacturing facilities in Biocon Park, Bangalore are USFDA, MHRA and EMA certified.
